دورية أكاديمية
Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase.
| العنوان: | Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase. |
|---|---|
| المؤلفون: | Myeni SK; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands. s.k.myeni@lumc.nl., Bredenbeek PJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Knaap RCM; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Dalebout TJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Morales ST; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Sidorov IA; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Linger ME; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Oreshkova N; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., van Zanen-Gerhardt S; Experimental Pathology Services Lab, Central Laboratory Animal Facility, Leiden University Medical Center, Leiden, The Netherlands., Zander SAL; Experimental Pathology Services Lab, Central Laboratory Animal Facility, Leiden University Medical Center, Leiden, The Netherlands., Enjuanes L; Department of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Campus Universidad Autonoma de Madrid, Madrid, Spain., Sola I; Department of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Campus Universidad Autonoma de Madrid, Madrid, Spain., Snijder EJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands., Kikkert M; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands. m.kikkert@lumc.nl. |
| المصدر: | Nature communications [Nat Commun] 2023 Feb 28; Vol. 14 (1), pp. 1141. Date of Electronic Publication: 2023 Feb 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Pub. Group |
| مواضيع طبية MeSH: | COVID-19 Vaccines*, Animals ; Humans ; Mice ; Deubiquitinating Enzymes ; Papain ; Peptide Hydrolases ; Vaccines, Attenuated ; Vaccine Development |
| مستخلص: | Coronaviruses express a papain-like protease (PLpro) that is required for replicase polyprotein maturation and also serves as a deubiquitinating enzyme (DUB). In this study, using a Middle East respiratory syndrome virus (MERS-CoV) PLpro modified virus in which the DUB is selectively inactivated, we show that the PLpro DUB is an important MERS-CoV interferon antagonist and virulence factor. Although the DUB-negative rMERS-CoV (© 2023. The Author(s).) |
| References: | Cell Host Microbe. 2020 May 13;27(5):736-751.e8. (PMID: 32330425) J Infect Dis. 2014 May 1;209(9):1331-42. (PMID: 24065148) J Korean Med Sci. 2016 Nov;31(11):1717-1725. (PMID: 27709848) Front Microbiol. 2019 Aug 02;10:1781. (PMID: 31428074) mSphere. 2017 Nov 15;2(6):. (PMID: 29152578) Exp Mol Med. 2021 May;53(5):723-736. (PMID: 33953325) Exp Mol Med. 2015 Aug 28;47:e181. (PMID: 26315600) Vaccines (Basel). 2020 Jun 17;8(2):. (PMID: 32560340) Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603. (PMID: 24062443) Lancet Infect Dis. 2020 Jul;20(7):816-826. (PMID: 32325038) Vet Pathol. 2013 Nov;50(6):1007-15. (PMID: 23558974) Vet Microbiol. 2015 Jul 9;178(1-2):132-7. (PMID: 25975520) Lancet Infect Dis. 2013 Oct;13(10):859-66. (PMID: 23933067) Crit Rev Biochem Mol Biol. 2017 Aug;52(4):425-460. (PMID: 28524749) Antiviral Res. 2020 Feb;174:104661. (PMID: 31765674) Biotechniques. 2006 Feb;40(2):191-7. (PMID: 16526409) Lancet Infect Dis. 2014 Feb;14(2):140-5. (PMID: 24355866) mBio. 2013 Sep 10;4(5):e00650-13. (PMID: 24023385) J Exp Med. 2016 Jan 11;213(1):1-13. (PMID: 26712804) J Virol. 2015 Apr;89(7):3659-70. (PMID: 25589660) J Virol. 2015 Apr;89(7):3859-69. (PMID: 25609809) J Biol Chem. 2014 Dec 12;289(50):34667-82. (PMID: 25320088) Nat Rev Microbiol. 2021 Mar;19(3):155-170. (PMID: 33116300) Sci Immunol. 2017 Aug 4;2(14):. (PMID: 28778905) Virology. 2014 Feb;450-451:64-70. (PMID: 24503068) Elife. 2018 Jan 16;7:. (PMID: 29336306) Annu Rev Immunol. 2018 Apr 26;36:667-694. (PMID: 29677479) BMC Genomics. 2014 Dec 22;15:1161. (PMID: 25534508) Viruses. 2010 Aug;2(8):1804-1820. (PMID: 21994708) Front Microbiol. 2021 Sep 28;12:752214. (PMID: 34659188) PLoS One. 2012;7(3):e32857. (PMID: 22412934) J Infect Dis. 2016 Mar 1;213(5):712-22. (PMID: 26486634) J Virol. 2021 Jan 13;95(3):. (PMID: 33144319) Cell Res. 2016 Apr;26(4):399-422. (PMID: 27012465) J Gen Virol. 2013 Nov;94(Pt 11):2367-2392. (PMID: 23999164) Adv Virus Res. 2016;96:219-243. (PMID: 27712625) PLoS Pathog. 2018 Sep 24;14(9):e1007296. (PMID: 30248143) Emerg Infect Dis. 2016 Oct;22(10):1813-6. (PMID: 27479636) Nat Rev Immunol. 2021 Feb;21(2):129. (PMID: 33402728) Lancet Infect Dis. 2018 Aug;18(8):e217-e227. (PMID: 29680581) Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128. (PMID: 28348219) N Engl J Med. 2017 Feb 9;376(6):584-594. (PMID: 28177862) Cell Host Microbe. 2017 Aug 9;22(2):176-184. (PMID: 28799903) Semin Immunopathol. 2017 Jul;39(5):529-539. (PMID: 28466096) PLoS Pathog. 2014 Aug 21;10(8):e1004250. (PMID: 25144235) mBio. 2017 Aug 22;8(4):. (PMID: 28830941) Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62. (PMID: 24043791) Lancet Infect Dis. 2020 Jul;20(7):827-838. (PMID: 32325037) Cell Host Microbe. 2009 Jun 18;5(6):559-70. (PMID: 19527883) Emerg Infect Dis. 2014 Dec;20(12):1999-2005. (PMID: 25418529) Immunity. 2019 Apr 16;50(4):907-923. (PMID: 30995506) mBio. 2012 Nov 20;3(6):. (PMID: 23170002) Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307) Adv Virus Res. 2016;96:245-286. (PMID: 27712626) Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347) Annu Rev Virol. 2019 Sep 29;6(1):567-584. (PMID: 31283436) Vaccine. 2013 Dec 16;31(52):6194-200. (PMID: 24183981) Nat Rev Mol Cell Biol. 2022 Jan;23(1):21-39. (PMID: 34824452) Virology. 2014 Apr;454-455:197-205. (PMID: 24725946) Nat Rev Immunol. 2014 Jan;14(1):36-49. (PMID: 24362405) Lancet Infect Dis. 2019 Sep;19(9):1013-1022. (PMID: 31351922) Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):8094-8103. (PMID: 32198201) Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E838-47. (PMID: 23401522) Biochem Biophys Res Commun. 2017 Oct 28;492(4):587-596. (PMID: 28576494) Future Microbiol. 2010 Jan;5(1):23-41. (PMID: 20020828) Cell Rep. 2017 Sep 5;20(10):2396-2407. (PMID: 28877473) mBio. 2021 Mar 2;12(2):. (PMID: 33653888) J Virol. 2020 May 18;94(11):. (PMID: 32188728) Nat Immunol. 2021 Nov;22(11):1416-1427. (PMID: 34663977) Commun Biol. 2018 Oct 29;1:179. (PMID: 30393776) Antiviral Res. 2018 Jan;149:58-74. (PMID: 29128390) Virus Res. 2014 Dec 19;194:184-90. (PMID: 24512893) |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) EC 3.4.19.12 (Deubiquitinating Enzymes) EC 3.4.22.2 (Papain) EC 3.4.- (Peptide Hydrolases) 0 (Vaccines, Attenuated) |
| تواريخ الأحداث: | Date Created: 20230228 Date Completed: 20230302 Latest Revision: 20230311 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9973250 |
| DOI: | 10.1038/s41467-023-36754-z |
| PMID: | 36854765 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!